Literature DB >> 29897294

DEPTOR at the Nexus of Cancer, Metabolism, and Immunity.

Alexandre Caron1, David M Briscoe1, Denis Richard1, Mathieu Laplante1.   

Abstract

DEP domain-containing mechanistic target of rapamycin (mTOR)-interacting protein (DEPTOR) is an important modulator of mTOR, a kinase at the center of two important protein complexes named mTORC1 and mTORC2. These highly studied complexes play essential roles in regulating growth, metabolism, and immunity in response to mitogens, nutrients, and cytokines. Defects in mTOR signaling have been associated with the development of many diseases, including cancer and diabetes, and approaches aiming at modulating mTOR activity are envisioned as an attractive strategy to improve human health. DEPTOR interaction with mTOR represses its kinase activity and rewires the mTOR signaling pathway. Over the last years, several studies have revealed key roles for DEPTOR in numerous biological and pathological processes. Here, we provide the current state of the knowledge regarding the cellular and physiological functions of DEPTOR by focusing on its impact on the mTOR pathway and its role in promoting health and disease.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29897294      PMCID: PMC6335100          DOI: 10.1152/physrev.00064.2017

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  23 in total

1.  Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of mTOR Activity Via DEPTOR.

Authors:  Rafael Cuesta; Marina A Gritsenko; Vladislav A Petyuk; Anil K Shukla; Chia-Feng Tsai; Tao Liu; Jason E McDermott; Marina K Holz
Journal:  Mol Cell Proteomics       Date:  2019-06-12       Impact factor: 5.911

2.  WNT pathway signaling is associated with microvascular injury and predicts kidney transplant failure.

Authors:  Michael E Seifert; Joseph P Gaut; Boyi Guo; Sanjay Jain; Andrew F Malone; Feargal Geraghty; Deborah L Della Manna; Eddy S Yang; Nengjun Yi; Daniel C Brennan; Roslyn B Mannon
Journal:  Am J Transplant       Date:  2019-05-10       Impact factor: 8.086

3.  Bipartite binding and partial inhibition links DEPTOR and mTOR in a mutually antagonistic embrace.

Authors:  Maren Heimhalt; Alex Berndt; Jane Wagstaff; Madhanagopal Anandapadamanaban; Olga Perisic; Sarah Maslen; Stephen McLaughlin; Conny Wing-Heng Yu; Glenn R Masson; Andreas Boland; Xiaodan Ni; Keitaro Yamashita; Garib N Murshudov; Mark Skehel; Stefan M Freund; Roger L Williams
Journal:  Elife       Date:  2021-09-14       Impact factor: 8.140

4.  DFNA5 inhibits colorectal cancer proliferation by suppressing the mTORC1/2 signaling pathways via upregulation of DEPTOR.

Authors:  Jing Guo; Junhui Yu; Mingchao Mu; Zilu Chen; Zhengshui Xu; Chenye Zhao; Kui Yang; Jianbao Zheng; Xiao Qin; Wei Zhao; Xuejun Sun
Journal:  Cell Cycle       Date:  2022-08-03       Impact factor: 5.173

Review 5.  Regulation of cellular anabolism by mTOR: or how I learned to stop worrying and love translation.

Authors:  J William Deaver; Sara Mata López; Patrick J Ryan; Peter P Nghiem; Steven E Riechman; James D Fluckey
Journal:  Sports Med Health Sci       Date:  2020-11-30

Review 6.  Regulation and metabolic functions of mTORC1 and mTORC2.

Authors:  Angelia Szwed; Eugene Kim; Estela Jacinto
Journal:  Physiol Rev       Date:  2021-02-18       Impact factor: 46.500

7.  Co-amplification of genes in chromosome 8q24: a robust prognostic marker in hepatocellular carcinoma.

Authors:  Yongjian Zheng; Yuan Cheng; Cheng Zhang; Shunjun Fu; Guolin He; Lei Cai; Ling Qiu; Kunhua Huang; Qunhui Chen; Wenzhuan Xie; Tingting Chen; Mengli Huang; Yuezong Bai; Mingxin Pan
Journal:  J Gastrointest Oncol       Date:  2021-06

8.  Deubiquitinase OTUD5 is a positive regulator of mTORC1 and mTORC2 signaling pathways.

Authors:  Jin Hwa Cho; Kidae Kim; Sung Ah Kim; Sungryul Park; Bi-Oh Park; Jong-Hwan Kim; Seon-Young Kim; Min Jee Kwon; Myeong Hoon Han; Sung Bae Lee; Byoung Chul Park; Sung Goo Park; Jeong-Hoon Kim; Sunhong Kim
Journal:  Cell Death Differ       Date:  2020-10-27       Impact factor: 15.828

9.  Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas.

Authors:  Zerui Wu; Yunqiu Xu; Jiadong Xu; Jianglong Lu; Lin Cai; Qun Li; Chengde Wang; Zhipeng Su
Journal:  Oxid Med Cell Longev       Date:  2021-06-16       Impact factor: 6.543

Review 10.  Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration.

Authors:  Jing Jin; Qijie Zhao
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.